文献速递间质性肺疾病肺栓塞与肺血管病

吡非尼酮加重系统性硬化症相关间质性肺病小鼠模型的Th2驱动血管病变

Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease.
PubMed 文献 · Eur Respir J · 2022-10-20

该研究在Fra-2过表达转基因和博来霉素诱导的SSc-ILD小鼠模型中评估吡非尼酮疗效。吡非尼酮减轻博来霉素模型肺重塑,但加重Fra-2转基因小鼠肺部炎症、纤维化及血管重塑,伴IL-4和嗜酸性粒细胞增多及内皮屏障损伤。提示在高Th2炎症和内皮损伤背景下,吡非尼酮抗纤维化作用可能被不利交互作用抵消。

要点

  • 吡非尼酮在博来霉素模型中减轻肺重塑,但在Fra-2转基因SSc-ILD模型中加重炎症、纤维化和血管重塑。
  • 吡非尼酮增加Fra-2转基因小鼠肺组织IL-4水平和嗜酸性粒细胞数量,体外不直接影响嗜酸性粒细胞活化与迁移。
  • 吡非尼酮加重IL-4诱导的内皮屏障阻力下降,促进白细胞跨内皮迁移。

核心结论

  • 在SSc-ILD模型中,吡非尼酮的抗纤维化特性可能被与预损伤内皮的不利交互作用所抵消,尤其在高Th2炎症背景下。

研究设计与样本

  • 研究在Fra-2过表达转基因(Fra-2 TG)和博来霉素处理的SSc-ILD小鼠模型中评估吡非尼酮对肺功能、炎症和胶原沉积的影响。
  • 对Fra-2 TG小鼠吡非尼酮治疗后进行肺转录组分析。
  • 体外使用流式细胞术评估吡非尼酮对人嗜酸性粒细胞功能的影响,并使用电阻抗测量评估对内皮细胞功能的影响。

主要发现

  • 吡非尼酮减轻博来霉素模型的肺重塑,但加重Fra-2 TG小鼠的肺部炎症、纤维化和血管重塑。
  • 吡非尼酮增加Fra-2 TG小鼠肺组织IL-4水平和嗜酸性粒细胞数量,体外不直接影响嗜酸性粒细胞活化和迁移。
  • 吡非尼酮处理的Fra-2 TG小鼠出现高水平细胞因子/趋化因子的显著免疫反应和低血管内皮钙黏蛋白(VE-cadherin)水平的内皮完整性破坏。
  • 博来霉素处理小鼠的嗜酸性粒细胞和VE-cadherin水平未变,且不受吡非尼酮影响。
  • 体外吡非尼酮加重IL-4诱导的内皮屏障阻力降低,导致更高白细胞跨内皮迁移。

临床怎么用

  • 对SSc-ILD患者使用吡非尼酮前可能需要仔细的ILD表型分析,以利用获益并避免治疗失败和额外肺损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic sclerosis (SSc) is an autoimmune disease characterised by severe vasculopathy and fibrosis of various organs including the lung. Targeted treatment options for SSc-associated interstitial lung disease (SSc-ILD) are scarce. We assessed the effects of pirfenidone in a mouse model of SSc-ILD. METHODS: Pulmonary function, inflammation and collagen deposition in response to pirfenidone were assessed in Fra-2-overexpressing transgenic (Fra-2 TG) and bleomycin-treated mice. In Fra-2 TG mice, lung transcriptome was analysed after pirfenidone treatment. In vitro, pirfenidone effects on human eosinophil and endothelial cell function were analysed using flow cytometry-based assays and electric cell-substrate impedance measurements, respectively. RESULTS: Pirfenidone treatment attenuated pulmonary remodelling in the bleomycin model, but aggravated pulmonary inflammation, fibrosis and vascular remodelling in Fra-2 TG mice. Pirfenidone increased interleukin (IL)-4 levels and eosinophil numbers in lung tissue of Fra-2 TG mice without directly affecting eosinophil activation and migration in vitro. A pronounced immune response with high levels of cytokines/chemokines and disturbed endothelial integrity with low vascular endothelial (VE)-cadherin levels was observed in pirfenidone-treated Fra-2 TG mice. In contrast, eosinophil and VE-cadherin levels were unchanged in bleomycin-treated mice and not influenced by pirfenidone. In vitro, pirfenidone exacerbated the IL-4 induced reduction of endothelial barrier resistance, leading to higher leukocyte transmigration. CONCLUSION: This study shows that antifibrotic properties of pirfenidone may be overruled by unwanted interactions with pre-injured endothelium in a setting of high T-helper type 2 inflammation in a model of SSc-ILD. Careful ILD patient phenotyping may be required to exploit benefits of pirfenidone while avoiding therapy failure and additional lung damage in some patients.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Birnhuber A, Jandl K, Biasin V, et al. Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease. Eur Respir J. 2022. PMID: 35332068. doi:10.1183/13993003.02347-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。